The use of unlicensed and off-label medicines in the neonate.
about
Drug-induced renal damage in preterm neonates: state of the art and methods for early detectionPattern of drug use among preterm neonates: results from an Italian neonatal intensive care unitMedication use in the neonatal intensive care unitThe launch of the British National Formulary for ChildrenRegulatory science needs for neonates: a call for neonatal community collaboration and innovationSuccessful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines.Pharmacokinetic research in children: an analysis of registered records of clinical trials.High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination.A prospective questionnaire assessment of attitudes and experiences of off label prescribing among hospital based paediatricians.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenTreating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.How to optimize the evaluation and use of antibiotics in neonatesHow well are general practice trainees prepared for paediatric prescribing?Public awareness and views on unlicensed use of medicines in childrenUse of non-formulary drugs in children at a Brazilian teaching hospital: a descriptive study.Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.Drugs and newborn.Inhibitors of gastric acid secretion drugs increase neonatal morbidity and mortality.Dosage individualization in children: integration of pharmacometrics in clinical practice.Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future.eNewborn: The Information Technology Revolution and Challenges for Neonatal Networks.A Computer Prescribing Order Entry-Clinical Decision Support system designed for neonatal care: results of the 'preselected prescription' concept at the bedside.Dose-Banding of Intravenous Piperacillin-Tazobactam in Pediatric Surgical Inpatients.Unlicensed and off-label drug use in a neonatal unit in France.Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.Collaboration in Regulatory Science to Facilitate Therapeutic Development for Neonates.Off-label drug use in a single-center pediatric cardiac intensive care unit.Perceptions and attitudes of Jordanian paediatricians towards off-label paediatric prescribingPharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry
P2860
Q26849339-708EC9EF-AF0C-41BA-A05F-FCF3B82AE89FQ33568454-2750FA83-D468-4C25-83D9-F296DA4C2134Q33769958-BB34CD5A-47A3-41C9-83B8-5FD649D8A766Q34452849-53E4EF10-4CC3-409D-906A-DE462CCBA43AQ34593375-6CDE48B2-B244-4BE0-9BA3-898E65C166AAQ35204915-503B2493-03D1-41C0-8C59-A7910DD33618Q35322451-CCC9F614-A16D-4B58-A161-17F2A52E6F21Q35532010-86F13DE2-F8DC-4001-9473-22211958989FQ36153091-81F6726B-84F9-4A6C-823B-2B6076EE13E9Q36322918-233109D7-1797-46C8-B9B7-921DB9E690B7Q36410220-5B2A13F3-9C05-47D6-95FA-9080B09073ADQ36452369-FE2F41CE-1E37-48D0-AC3C-FDD990F2939CQ37173981-9F8D0232-D3C7-4F74-AF13-56CAAF2666E0Q37175765-D5A83C48-42E4-4875-B86A-8BDE58A63F93Q37190965-6F842C12-8336-4915-92B9-474139ECA167Q37470692-0F493B84-9A9C-4D3D-A84C-AAC52EED2BC5Q37635184-2F602E76-3DE5-4DD1-9FD8-8EE4E7DF35ABQ38041609-25E13A43-1D49-4769-934E-20A5FA77783FQ38240055-73EEF5A9-CFD0-4421-ADC6-1268D65ACE1FQ38563371-E51F92A8-6442-4041-93FA-2DBFFA083E49Q38679826-12A7E1E7-C2BF-4E2E-B4BA-778C55581315Q39157192-F0E02F83-2F2D-45CA-909C-40AB4AF08BD7Q42376930-92C64C76-3B94-4811-83FD-46AE1EBDF0F9Q43608412-3C0E053D-2B83-46A3-B33B-3AD5A443BC45Q47205248-E2079F67-1CCA-4F2D-B752-B75665982429Q47428031-23AC9495-2791-48E3-BB9E-DCFF8488BD20Q47580566-7198D6B0-2243-4D50-868A-7267F844A0A0Q47917646-C044EED4-310A-4213-B338-A94FB30E338AQ54457383-DF566615-0229-46FA-ABB8-28C35F3319FEQ56775908-6970F5E1-C0F6-4A3B-AB0A-E689CEE50A70Q57150351-EA2B1BD8-0CB9-4DF1-ABFD-222EEFD60ECD
P2860
The use of unlicensed and off-label medicines in the neonate.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The use of unlicensed and off-label medicines in the neonate.
@ast
The use of unlicensed and off-label medicines in the neonate.
@en
type
label
The use of unlicensed and off-label medicines in the neonate.
@ast
The use of unlicensed and off-label medicines in the neonate.
@en
prefLabel
The use of unlicensed and off-label medicines in the neonate.
@ast
The use of unlicensed and off-label medicines in the neonate.
@en
P1476
The use of unlicensed and off-label medicines in the neonate.
@en
P2093
John McIntyre
Sharon Conroy
P304
P356
10.1016/J.SINY.2004.11.003
P577
2005-01-25T00:00:00Z